HB-101 is a Recombinant Vector Vaccine owned by Hookipa Pharma, and is involved in 2 clinical trials, which were completed.

HB-101 acts by stimulating the immune response against pp65 protein and gB protein of human cytomegalovirus. The gene expressed on the vector acts as antigen and induces adaptive and innate immune responses by activating B-cells and CD8 T-cells.

The revenue for HB-101 is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the HB-101 NPV Report.

HB-101 is originated and owned by Hookipa Pharma.

HB-101 Overview

HB-101 (Vaxwave) is under development for the prevention of cytomegalovirus infections in solid organ transplant patients. It is administered intramuscularly. It is a bivalent vaccine containing two recombinant, replication-deficient lymphocytic choriomeningitis virus (rLCMV) vectors, one expressing the pp65 protein and one expressing the gB protein of human cytomegalovirus (HCMV). It is based on Vaxwave technology.

Hookipa Pharma Overview

Hookipa Pharma (Hookipa) is a clinical-stage biopharmaceutical company that develops novel class of immunotherapeutics against infectious diseases and cancers. Its pipeline products include HB-101, a prophylactic cytomegalovirus vaccine candidate; HB-202 and HB-201, immuno-oncology product candidates for the treatment of human papillomavirus-positive cancers; and HB-301, targeting prostate cancer. Hookipa’s proprietary arenavirus-based technologies, VaxWave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce antigen specific cytotoxic T cells and pathogen-neutralizing antibodies for prophylactic and therapeutic purposes activating body’s immune response. The company collaborates with Gilead Sciences Inc for the development of immunotherapies to treat HIV and Hepatitis B. It operates a research and preclinical development center in Vienna, Austria. Hookipa is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$18.5 million for the fiscal year ended December 2021 (FY2021), a decrease of 5.8% over FY2020. The operating loss of the company was US$81.7 million in FY2021, compared to an operating loss of US$53.3 million in FY2020. The net loss of the company was US$75.7 million in FY2021, compared to a net loss of US$44.1 million in FY2020. The company reported revenues of US$2.2 million for the third quarter ended September 2022, a decrease of 18.8% over the previous quarter.

Quick View – HB-101

Report Segments
  • Innovator
Drug Name
  • HB-101
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.